An 18-kDa Translocator Protein (TSPO) Polymorphism I
Affinity of the PET Radioligand PBR28

Journal of Cerebral Blood Flow and Metabolism

32, 1-5

DOI: 10.1038/jcbfm.2011.147

Citation Report

#	Article	IF	Citations
3	Translocator Protein (18â€‰kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [¹⁸F]-FEPPA. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 968-972.	4.3	131
4	Rethinking the purinergic neuronâ€“glia connection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5913-5914.	7.1	15
5	Aspects of Astrocyte Energy Metabolism, Amino Acid Neurotransmitter Homoeostasis and Metabolic Compartmentation. ASN Neuro, 2012, 4, AN20120007.	2.7	70
6	The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology, 2012, 92, 959-975.	3.3	293
7	Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. NeuroImage, 2012, 60, 902-910.	4.2	73
8	Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. NeuroImage, 2012, 63, 232-239.	4.2	179
9	PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy. EJNMMI Research, 2012, 2, 60.	2.5	78
10	Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. EJNMMI Research, 2012, 2, 15.	2.5	86
11	The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 811-823.	6.4	80
12	Positron emission tomography molecular imaging for drug development. British Journal of Clinical Pharmacology, 2012, 73, 175-186.	2.4	263
13	The early contribution of cerebrovascular factors to the pathogenesis of Alzheimerâ€™s disease. European Journal of Neuroscience, 2012, 35, 1917-1937.	2.6	77
14	In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Research, 2013, 3, 30.	2.5	66
15	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain, Behavior, and Immunity, 2013, 33, 131-138.	4.1	180
16	In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimerâ€™s disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 921-931.	6.4	71
17	Structureâ€“activity relationships of novel iodinated quinoline-2-carboxamides for targeting the translocator protein. MedChemComm, 2013, 4, 1461.	3.4	13
18	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18ÂkDa). Molecular Imaging and Biology, 2013, 15, 353-359.	2.6	23
19	Quantification of the Specific Translocator Protein Signal of ¹⁸F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. Journal of Nuclear Medicine, 2013, 54, 1915-1923.	5.0	105
20	Distribution physiologique cÃ©rÃ©brale et corps entier du 18F-DPA-714Âen TEP/TDM. Medecine Nucleaire, 2013, 37, 44-51.	0.2	0

#	Article	IF	Citations
21	Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18kDa Translocator Protein (TSPO). Psychoneuroendocrinology, 2013, 38, 2826-2829.	2.7	47
22	Graphic plot analysis for estimating binding potential of translocator protein (TSPO) in positron emission tomography studies with [18F]FEDAA1106. NeuroImage, 2013, 69, 78-86.	4.2	5
23	P.4.024 Using positron emission tomography to investigate microglial activation in alcohol dependence: preliminary findings. European Neuropsychopharmacology, 2013, 23, S87-S88.	0.7	0
24	Positron-Emission Tomography Imaging of the TSPO with [¹⁸F]FEPPA in a Preclinical Breast Cancer Model. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 254-259.	1.0	17
25	Chemical Catalysis by the Translocator Protein (18 kDa). Biochemistry, 2013, 52, 3609-3611.	2.5	32
26	The translocator protein (TSPO): A novel target for cancer chemotherapy. International Journal of Biochemistry and Cell Biology, 2013, 45, 1212-1216.	2.8	82
27	Characterization and Modeling of the Oligomeric State and Ligand Binding Behavior of Purified Translocator Protein 18 kDa from Rhodobacter sphaeroides. Biochemistry, 2013, 52, 5884-5899.	2.5	53
28	In vivo radioligand binding to translocator protein correlates with severity of Alzheimerâ€™s disease. Brain, 2013, 136, 2228-2238.	7.6	280
29	A Genetic Polymorphism for Translocator Protein 18 Kda Affects bothin Vitroandin VivoRadioligand Binding in Human Brain to this Putative Biomarker of Neuroinflammation. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 53-58.	4.3	207
30	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. Journal of Psychopharmacology, 2013, 27, 119-122.	4.0	16
31	Propofol Decreases In Vivo Binding of ¹¹C-PBR28 to Translocator Protein (18 kDa) in the Human Brain. Journal of Nuclear Medicine, 2013, 54, 64-69.	5.0	30
32	Influence of TSPO Genotype on ¹¹C-PBR28 Standardized Uptake Values. Journal of Nuclear Medicine, 2013, 54, 1320-1322.	5.0	56
33	Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?. Synapse, 2013, 67, 909-912.	1.2	21
34	In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4â€²-¹²³I-Iodophenyl)-3-(N,N-Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT. Journal of Nuclear Medicine, 2014, 55, 1966-1972.	5.0	16
35	Determination of [¹¹C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 989-994.	4.3	117
36	A Graphical Method to Compare the in vivo Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [¹¹C]PBR28 and [¹⁸F]PBR111 for TSPO Imaging. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1162-1168.	4.3	38
37	The translocator protein as a drug target in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 439-448.	2.8	20
38	Hemichannels: new roles in astroglial function. Frontiers in Physiology, 2014, 5, 193.	2.8	77

#	Article	IF	Citations
39	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. Future Neurology, 2014, 9, 597-613.	0.5	3
40	The 18â€‰<scp>kDa</scp> Translocator Protein, Microglia and Neuroinflammation. Brain Pathology, 2014, 24, 631-653.	4.1	182
41	Regional variations in vascular density correlate with restingâ€state and taskâ€evoked blood oxygen levelâ€dependent signal amplitude. Human Brain Mapping, 2014, 35, 1906-1920.	3.6	59
42	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸F]â€FEPPA. Synapse, 2014, 68, 536-547.	1.2	17
43	Microglia of Prefrontal White Matter in Suicide. Journal of Neuropathology and Experimental Neurology, 2014, 73, 880-890.	1.7	150
44	Neuroinflammation and ï¿½ Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging. Dementia and Geriatric Cognitive Disorders, 2014, 37, 1-18.	1.5	21
45	Developments in neuroimaging: positron emission tomography. Parkinsonism and Related Disorders, 2014, 20, S180-S183.	2.2	12
46	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875.	4.2	56
47	Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1550-1556.	2.2	38
48	Immunological Mechanisms and Therapies in Brain Injuries and Stroke. , 2014, , .		4
49	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. Journal of NeuroVirology, 2014, 20, 219-232.	2.1	78
50	Characterization of a novel acetamidobenzoxazoloneâ€based PET ligand for translocator protein (18ÂkDa) imaging of neuroinflammation in the brain. Journal of Neurochemistry, 2014, 129, 712-720.	3.9	39
51	Toward the functional oligomerization state of tryptophanâ€rich sensory proteins. Protein Science, 2014, 23, 1154-1160.	7.6	8
52	[¹⁸F]DPAâ€C5yne, a novel fluorineâ€18â€labelled analogue of DPAâ€714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 410-418.	1.0	11
53	Understanding the pharmacology of stroke and multiple sclerosis through imaging. Current Opinion in Pharmacology, 2014, 14, 34-41.	3.5	1
54	Facile synthesis of SSR180575 and discovery of 7-chloro- N , N ,5-trimethyl-4-oxo-3(6-[18) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 ligand for PET imaging of TSPO in cancer. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4466-4471.	2.2	21
55	Cocaine Abuse in Humans Is Not Associated with Increased Microglial Activation: An 18-kDa Translocator Protein Positron Emission Tomography Imaging Study with [11C]PBR28. Journal of Neuroscience, 2014, 34, 9945-9950.	3.6	55
56	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸F-PBR111 PET. Journal of Nuclear Medicine, 2014, 55, 1112-1118.	5.0	82

#	Article	IF	Citations
57	Development of N-Methyl-(2-arylquinolin-4-yl)oxypropanamides as Leads to PET Radioligands for Translocator Protein (18 kDa). Journal of Medicinal Chemistry, 2014, 57, 6240-6251.	6.4	21
58	On the Role of the Translocator Protein (18-kDa) TSPO in Steroid Hormone Biosynthesis. Endocrinology, 2014, 155, 15-20.	2.8	38
59	Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Translational Psychiatry, 2014, 4, e350-e350.	4.8	80
60	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. ACS Chemical Neuroscience, 2014, 5, 963-971.	3.5	91
61	Preventing Vascular Effects on Brain Injury and Cognition Late in Life: Knowns and Unknowns. Neuropsychology Review, 2014, 24, 371-387.	4.9	15
62	Tracking neuroinflammation in Alzheimerâ€™s disease: the role of positron emission tomography imaging. Journal of Neuroinflammation, 2014, 11, 120.	7.2	89
63	Nuclear imaging: A powerful novel approach for tuberculosis. Nuclear Medicine and Biology, 2014, 41, 777-784.	0.6	28
64	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 2014, 16, R70.	3.5	32
65	Could 18â€‰F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. EJNMMI Research, 2014, 4, 28.	2.5	40
66	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurology, The, 2014, 13, 807-822.	10.2	197
68	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet, The, 2014, 384, 532-544.	13.7	129
70	Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study. Journal of Nuclear Medicine, 2014, 55, 945-950.	5.0	254
71	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195. Journal of Nuclear Medicine, 2014, 55, 939-944.	5.0	132
72	Imaging brain inflammation in epilepsy. Neuroscience, 2014, 279, 238-252.	2.3	44
73	Evaluation of neuroprotective effect of glucagonâ€like peptide 1 analogs using neuroimaging. Alzheimer's and Dementia, 2014, 10, S55-61.	0.8	36
74	Utility of 18â€‰F-FDG and 11C-PBR28 microPET for the assessment of rat aortic aneurysm inflammation. EJNMMI Research, 2014, 4, 20.	2.5	15
75	Translocator protein and new targets for neuroinflammation. Clinical and Translational Imaging, 2015, 3, 391-402.	2.1	23
76	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110

#	Article	IF	Citations
77	The methodology of TSPO imaging with positron emission tomography. Biochemical Society Transactions, 2015, 43, 586-592.	3.4	186
78	Structure of the mammalian TSPO/PBR protein. Biochemical Society Transactions, 2015, 43, 566-571.	3.4	29
79	Translocator protein: pharmacology and steroidogenesis. Biochemical Society Transactions, 2015, 43, 572-578.	3.4	37
80	The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside. Biochemical Society Transactions, 2015, 43, 579-585.	3.4	19
81	Inflammation and Suicidal Behavior. Advances in Biological Psychiatry, 2016, , 123-144.	0.2	3
82	PET Imaging in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 287-296.	1.9	16
83	Challenges of quantification of TSPO in the human brain. Clinical and Translational Imaging, 2015, 3, 403-416.	2.1	16
84	TSPO imaging in stroke: from animal models to human subjects. Clinical and Translational Imaging, 2015, 3, 423-435.	2.1	14
85	Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. Journal of Neuroinflammation, 2015, 12, 108.	7.2	51
86	Radiosynthesis and Preliminary Biological Evaluation of [¹⁸F]VC701, a Radioligand for Translocator Protein. Molecular Imaging, 2015, 14, 7290.2015.00007.	1.4	16
87	Structural Integrity of the A147T Polymorph of Mammalian TSPO. ChemBioChem, 2015, 16, 1483-1489.	2.6	32
88	[¹⁸F]FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and in vitro Autoradiograms of the Human Brain. Theranostics, 2015, 5, 961-969.	10.0	45
89	Imaging Striatal Microglial Activation in Patients with Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0138721.	2.5	95
90	Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7261-7266.	7.1	115
91	Lost in translocation: the functions of the 18-kD translocator protein. Trends in Endocrinology and Metabolism, 2015, 26, 349-356.	7.1	60
92	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.8	66
93	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics, 2015, 16, 5-22.	1.3	15
94	Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clinical, 2015, 7, 409-414.	2.7	176

#	Article	IF	Citations
95	Identification of a Key Cholesterol Binding Enhancement Motif in Translocator Protein 18 kDa. Biochemistry, 2015, 54, 1441-1443.	2.5	27
96	Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science, 2015, 347, 555-558.	12.6	143
97	Structure and activity of tryptophan-rich TSPO proteins. Science, 2015, 347, 551-555.	12.6	149
98	Evidence for brain glial activation in chronic pain patients. Brain, 2015, 138, 604-615.	7.6	372
99	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA. Schizophrenia Bulletin, 2015, 41, 85-93.	4.3	158
100	The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹C-(R)PK11195 PET Imaging and Neuropathology Study. Journal of Nuclear Medicine, 2015, 56, 512-517.	5.0	77
101	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinsonâ€™s disease. Brain, 2015, 138, 2687-2700.	7.6	168
102	How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?. Current Neurology and Neuroscience Reports, 2015, 15, 53.	4.2	5
103	In-vivo imaging of grey and white matter neuroinflammation in Alzheimerâ€™s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Molecular Psychiatry, 2015, 20, 1579-1587.	7.9	101
104	Roles of microglia in brain development, tissue maintenance and repair. Brain, 2015, 138, 1138-1159.	7.6	316
105	11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1081-1092.	6.4	77
106	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry, 2015, 72, 268.	11.0	700
107	Evolving understanding of translocator protein 18kDa (TSPO). Pharmacological Research, 2015, 99, 404-409.	7.1	26
108	Minireview: Translocator Protein (TSPO) and Steroidogenesis: A Reappraisal. Molecular Endocrinology, 2015, 29, 490-501.	3.7	63
109	Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. CNS Drugs, 2015, 29, 313-330.	5.9	14
110	Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis. Molecular and Cellular Endocrinology, 2015, 408, 90-98.	3.2	103
111	Advanced imaging tools to investigate multiple sclerosis pathology. Presse Medicale, 2015, 44, e159-e167.	1.9	19
112	Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. Journal of Nuclear Medicine, 2015, 56, 701-706.	5.0	183

#	Article	IF	Citations
113	Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. Expert Opinion on Drug Discovery, 2015, 10, 557-570.	5.0	27
114	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12468-12473.	7.1	265
115	PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nuclear Medicine and Biology, 2015, 42, 753-761.	0.6	48
116	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2015, 58, 8743-8749.	6.4	12
117	Quantitative imaging of protein targets in the human brain with PET. Physics in Medicine and Biology, 2015, 60, R363-R411.	3.0	61
118	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clinical and Translational Imaging, 2015, 3, 461-473.	2.1	41
119	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. Journal of Nuclear Medicine, 2015, 56, 707-713.	5.0	30
120	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 2015, 74, 58-65.	4.4	208
121	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimerâ€™s disease patients and control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 438-446.	6.4	64
122	Tetrapyrroles as Endogenous TSPO Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic Ligands. International Journal of Molecular Sciences, 2016, 17, 880.	4.1	36
123	Indications of success: Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development. International Journal of Neuropsychopharmacology, 2017, 20, pyw111.	2.1	19
124	Drug Development in Alzheimerâ€™s Disease: The Contribution of PET and SPECT. Frontiers in Pharmacology, 2016, 7, 88.	3.5	22
127	Biomarkers for drug development in early psychosis: Current issues and promising directions. European Neuropsychopharmacology, 2016, 26, 923-937.	0.7	37
128	11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiology of Aging, 2016, 44, 53-61.	3.1	135
129	Pharmacokinetic Analysis of ¹¹C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with (R)-¹¹C-PK11195. Journal of Nuclear Medicine, 2016, 57, 785-791.	5.0	21
130	Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 819-830.	4.3	5
131	PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. Molecular Imaging and Biology, 2016, 18, 724-732.	2.6	35
132	Molecular Imaging of Inflammation: Current Status. Journal of Nuclear Medicine, 2016, 57, 1161-1165.	5.0	40

#	Article	IF	Citations
133	Current status and future perspectives: TSPO in steroid neuroendocrinology. Journal of Endocrinology, 2016, 231, R1-R30.	2.6	32
134	Neuroinflammatory component of gray matter pathology in multiple sclerosis. Annals of Neurology, 2016, 80, 776-790.	5.3	150
135	The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia. Brain, Behavior, and Immunity, 2016, 58, 218-227.	4.1	39
136	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1â€"Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ¹¹C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. Journal of Nuclear Medicine, 2016, 57, 1905-1912.	5.0	18
137	Genetic and degenerative disorders primarily causing dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 525-564.	1.8	5
138	Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2201-2210.	6.4	70
139	The neuroendocrinology of stress in the pathophysiology of bipolar disorders. , 0, , 90-101.		0
140	Test-retest analysis of a non-invasive method of quantifying [11C]-PBR28 binding in Alzheimerâ€™s disease. EJNMMI Research, 2016, 6, 72.	2.5	25
141	Positron emission tomography imaging of coronary atherosclerosis. Future Cardiology, 2016, 12, 483-496.	1.2	9
142	Preclinical Evaluation of a P2X7 Receptorâ€"Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	5.0	77
143	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain, Behavior, and Immunity, 2016, 54, 149-157.	4.1	48
144	TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?. Clinical and Translational Imaging, 2016, 4, 145-156.	2.1	57
146	Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biological Psychiatry, 2016, 80, 62-72.	1.3	103
147	In Vivo Imaging of Human Neuroinflammation. ACS Chemical Neuroscience, 2016, 7, 470-483.	3.5	165
148	Neuroinflammation in treated HIV-positive individuals. Neurology, 2016, 86, 1425-1432.	1.1	136
149	Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 2016, 40, 72-81.	0.2	5
150	TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria. Biochemical Journal, 2016, 473, 107-121.	3.7	67
151	Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?. Journal of Nuclear Medicine, 2016, 57, 165-168.	5.0	145

#	Article	IF	Citations
152	Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Molecular Psychiatry, 2016, 21, 10-28.	7.9	85
153	Backbone and side-chain resonance assignment of the A147T polymorph of mouse TSPO in complex with a high-affinity radioligand. Biomolecular NMR Assignments, 2016, 10, 79-83.	0.8	8
154	Testâ€"retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 173-183.	6.4	106
155	Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [¹¹C]PBR28 PET Brain Imaging Study. American Journal of Psychiatry, 2016, 173, 44-52.	7.2	382
156	Microglial activation and progressive brain changes in schizophrenia. British Journal of Pharmacology, 2016, 173, 666-680.	5.4	185
157	Depiction of microglial activation in aging and dementia: Positron emission tomography with [¹¹C]DPA713 versus [¹¹C](R)PK11195. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 877-889.	4.3	62
158	Microglial phenotypes in Parkinsonâ€™s disease and animal models of the disease. Progress in Neurobiology, 2017, 155, 57-75.	5.7	202
159	Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease. Neurobiology of Aging, 2017, 51, 132-140.	3.1	39
160	PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 895-902.	6.4	22
161	Microglial activation in Parkinsonâ€™s disease using [18F]-FEPPA. Journal of Neuroinflammation, 2017, 14, 8.	7.2	88
162	Decreased hippocampal translocator protein (18â€‰kDa) expression in alcohol dependence: a [11C]PBR28 PET study. Translational Psychiatry, 2017, 7, e996-e996.	4.8	56
163	Modified benzoxazolone derivative as 18â€<scp>kD</scp>a <scp>TSPO</scp> ligand. Chemical Biology and Drug Design, 2017, 90, 511-519.	3.2	13
164	Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 Positron Emission Tomography Study. Neuropsychopharmacology, 2017, 42, 1630-1639.	5.4	47
165	Neuroinflammation in Neurodegenerative Disordersâ€"a Review. Current Neurology and Neuroscience Reports, 2017, 17, 25.	4.2	240
166	In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Molecular Psychiatry, 2017, 22, 1759-1766.	7.9	64
167	Development of a ¹⁸F-Labeled Radiotracer with Improved Brain Kinetics for Positron Emission Tomography Imaging of Translocator Protein (18 kDa) in Ischemic Brain and Glioma. Journal of Medicinal Chemistry, 2017, 60, 4047-4061.	6.4	22
168	Imaging in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 233-274.	2.0	21
169	Brain microglia in psychiatric disorders. Lancet Psychiatry,the, 2017, 4, 563-572.	7.4	208

#	Article	IF	Citations
170	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 42-47.	2.0	28
171	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1469-1478.	3.0	23
172	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. JAMA Neurology, 2017, 74, 67.	9.0	134
173	Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology, 2017, 56, 1837-1846.	1.9	22
174	The 18 kDa Translocator Protein (TSPO): Cholesterol Trafficking and the Biology of a Prognostic and Therapeutic Mitochondrial Target. Biological and Medical Physics Series, 2017, , 285-315.	0.4	2
175	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry, 2017, 74, 833.	11.0	132
176	Pro-inflammatory activation of primary microglia and macrophages increases 18â€‰kDa translocator protein expression in rodents but not humans. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2679-2690.	4.3	153
177	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [18F]FEPPA. Neuropsychopharmacology, 2017, 42, 2474-2481.	5.4	47
178	¹¹C-PBR28 and ¹⁸F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1477-1482.	5.0	57
179	Two populations of TSPO binding sites in oral cancer SCC-15 cells. Experimental Cell Research, 2017, 350, 279-283.	2.6	3
180	Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. Seminars in Nuclear Medicine, 2017, 47, 54-63.	4.6	15
181	TSPO PET using 18F-GE-180: a new perspective in neurooncology?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2227-2229.	6.4	5
182	The translocator protein (18 kDa) and its role in neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2017, 83, 183-199.	6.1	23
183	Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain, 2017, 140, 2927-2938.	7.6	75
184	Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. Seminars in Nuclear Medicine, 2017, 47, 429-453.	4.6	25
185	Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. Nuclear Medicine Communications, 2017, 38, 372-382.	1.1	57
186	Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies. International Review of Psychiatry, 2017, 29, 555-566.	2.8	6
187	TSPO mutations in rats and a human polymorphism impair the rate of steroid synthesis. Biochemical Journal, 2017, 474, 3985-3999.	3.7	80

#	Article	IF	Citations
188	[11C]-(R)-PK11195 positron emission tomography in patients with complex regional pain syndrome. Medicine (United States), 2017, 96, e5735.	1.0	40
189	Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nuclear Medicine and Molecular Imaging, 2017, 51, 283-296.	1.0	80
190	Imaging in Central Nervous System Drug Discovery. Seminars in Nuclear Medicine, 2017, 47, 89-98.	4.6	38
191	Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal ¹⁸F-FDG and ¹⁸F-DPA-714 PET imaging. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2870-2882.	4.3	53
192	The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo ¹²³I-CLINDE SPECT Imaging: A Testâ€"Retest Study. Journal of Nuclear Medicine, 2017, 58, 989-995.	5.0	7
193	Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 296-307.	6.4	19
194	Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Multiple Sclerosis Journal, 2017, 23, 496-504.	3.0	24
195	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.4	12
196	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	2.6	58
197	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸F]FEPPA. American Journal of Psychiatry, 2017, 174, 118-124.	7.2	103
198	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	1.6	25
199	Targeting Neuroinflammation to Treat Alzheimerâ€™s Disease. CNS Drugs, 2017, 31, 1057-1082.	5.9	182
200	TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Research, 2017, 7, 89.	2.5	55
201	Microglial Activation in Traumatic Brain Injury. Frontiers in Aging Neuroscience, 2017, 9, 208.	3.4	307
202	Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism. Frontiers in Aging Neuroscience, 2017, 9, 229.	3.4	12
203	Biomarkers for Alzheimerâ€™s Disease. , 2017, , 247-277.		0
204	TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?. Contrast Media and Molecular Imaging, 2017, 2017, 1-17.	0.8	32
205	Molecular Imaging of Neuroinflammation in Neurodegenerative Dementias: The Role of In Vivo PET Imaging. International Journal of Molecular Sciences, 2017, 18, 993.	4.1	64

#	Article	IF	Citations
206	Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Research, 2017, 7, 58.	2.5	33
207	Comparison of four 11C-labeled PET ligands to quantify translocator protein 18ÂkDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176â€"based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Research, 2017, 7, 84.	2.5	80
208	A Model to Explain 11C-PBR28 SUV Profile in Parkinsonâ€™s disease and Unaffected Lrrk2 Mutation Carriers. , 2017, , .		0
209	Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. International Journal of Molecular Sciences, 2017, 18, 802.	4.1	101
210	The emerging role of PET imaging in dementia. F1000Research, 2017, 6, 1830.	1.6	43
211	Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery. , 2017, , 20-64.		4
212	Molecular imaging of neuroinflammation in preclinical rodent models using positron emission tomography. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 60-75.	0.7	4
213	[¹⁸F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity, and Preliminary in Vitro Evaluation in Colorectal Cancer. ACS Medicinal Chemistry Letters, 2018, 9, 177-181.	2.8	15
214	Imaging Macrophage-associated Inflammation. Seminars in Nuclear Medicine, 2018, 48, 242-245.	4.6	14
215	TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsingâ€"remitting multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1423-1431.	6.4	53
216	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biological Psychiatry, 2018, 84, 433-442.	1.3	103
217	Perturbations of Native Membrane Protein Structure in Alkyl Phosphocholine Detergents: A Critical Assessment of NMR and Biophysical Studies. Chemical Reviews, 2018, 118, 3559-3607.	47.7	132
218	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry,the, 2018, 5, 339-347.	7.4	192
219	Mitochondrial function in individuals at clinical high risk for psychosis. Scientific Reports, 2018, 8, 6216.	3.3	23
220	Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder. Psychoneuroendocrinology, 2018, 89, 194-202.	2.7	20
221	Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain, 2018, 159, 968-977.	4.2	109
222	Head-to-Head Comparison of ¹¹C-PBR28 and ¹⁸F-GE180 for Quantification of the Translocator Protein in the Human Brain. Journal of Nuclear Medicine, 2018, 59, 1260-1266.	5.0	48
223	Update on Molecular Imaging in Parkinsonâ€™s Disease. Neuroscience Bulletin, 2018, 34, 330-340.	2.9	19

#	Article	IF	Citations
224	Sifting through the surfeit of neuroinflammation tracers. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 204-224.	4.3	92
225	Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. Journal of Nuclear Medicine, 2018, 59, 1125-1132.	5.0	46
226	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain, 2018, 141, 459-471.	7.6	143
227	Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. Autoimmunity Reviews, 2018, 17, 715-726.	5.8	53
228	PET Imaging in Psychoneuroimmunology Research. Methods in Molecular Biology, 2018, 1781, 287-307.	0.9	1
229	Neuroinflammation in Huntingtonâ€™s Disease: New Insights with ¹¹C-PBR28 PET/MRI. ACS Chemical Neuroscience, 2018, 9, 2563-2571.	3.5	60
230	[¹¹ C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology, 2018, 90, e1989-e1996.	1.1	89
231	Microglial Activation on 11C-CB184 PET in a Patient With Cerebellar Ataxia Associated With HIV Infection. Clinical Nuclear Medicine, 2018, 43, e82-e84.	1.3	4
232	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	6.4	22
233	Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry, 2018, 23, 323-334.	7.9	159
234	Validation of an automatic reference region extraction for the quantification of [¹⁸F]DPA-714 in dynamic brain PET studies. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 333-346.	4.3	32
235	In vivo PET imaging of neuroinflammation in Alzheimerâ€™s disease. Journal of Neural Transmission, 2018, 125, 847-867.	2.8	52
236	Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 123-131.	4.8	76
237	Kinetic modelling of [¹¹C]PBR28 for 18â€‰kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1227-1242.	4.3	51
238	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Molecular Imaging and Biology, 2018, 20, 94-102.	2.6	88
239	Translocator protein (18ÂkDa): an update on its function in steroidogenesis. Journal of Neuroendocrinology, 2018, 30, e12500.	2.6	83
240	Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study. Brain, Behavior, and Immunity, 2018, 68, 146-157.	4.1	17
241	Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353.	2.7	29

#	Article	IF	Citations
242	Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study. Schizophrenia Research, 2018, 195, 206-214.	2.0	48
243	The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. Journal of NeuroImmune Pharmacology, 2018, 13, 1-5.	4.1	14
244	Pseudoreference Regions for Glial Imaging with ¹¹C-PBR28: Investigation in 2 Clinical Cohorts. Journal of Nuclear Medicine, 2018, 59, 107-114.	5.0	32
245	Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study. Journal of the Neurological Sciences, 2018, 385, 30-33.	0.6	10
246	Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1885-1895.	4.3	29
247	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biological Psychiatry, 2018, 83, 61-69.	1.3	266
248	UEG Week 2018 Poster Presentations. United European Gastroenterology Journal, 2018, 6, A135.	3.8	27
249	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Research, 2018, 8, 57.	2.5	144
250	Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain, 2018, 141, 3415-3427.	7.6	95
251	Imaging and Molecular Mechanisms of Alzheimerâ€™s Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702.	4.1	45
252	Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET. European Journal of Medicinal Chemistry, 2018, 159, 292-306.	5.5	13
253	Effect of overnight smoking abstinence on a marker for microglial activation: a [11C]DAA1106 positron emission tomography study. Psychopharmacology, 2018, 235, 3525-3534.	3.1	23
254	Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 314.	3.4	60
255	Positron Emission Tomography Imaging of Macrophages in Atherosclerosis with ¹⁸F-GE-180, a Radiotracer for Translocator Protein (TSPO). Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	27
256	PET/CT of Dementia. American Journal of Roentgenology, 2018, 211, 246-259.	2.2	18
257	(Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia. Schizophrenia Bulletin, 2018, 44, 948-957.	4.3	21
258	Imaging in Pharmacogenetics. Advances in Pharmacology, 2018, 83, 95-107.	2.0	2
259	In vivo Imaging of Glial Activation in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 625.	2.4	71

#	Article	IF	Citations
260	In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation. Theranostics, 2018, 8, 2603-2620.	10.0	36
261	Microglial activation correlates in vivo with both tau and amyloid in Alzheimerâ€™s disease. Brain, 2018, 141, 2740-2754.	7.6	143
262	The Aging of Iron Man. Frontiers in Aging Neuroscience, 2018, 10, 65.	3.4	121
263	Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. Frontiers in Neurology, 2018, 9, 181.	2.4	51
264	Preclinical comparison study between [18F]fluoromethyl-PBR28 and its deuterated analog in a rat model of neuroinflammation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2925-2929.	2.2	15
265	Effects of genetic variants in the TSPO gene on protein structure and stability. PLoS ONE, 2018, 13, e0195627.	2.5	19
266	In vivo quantification of glial activation in minipigs overexpressing human Î±â€synuclein. Synapse, 2018, 72, e22060.	1.2	15
267	In VivoMRI of Functionalized Iron Oxide Nanoparticles for Brain Inflammation. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	23
268	In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration. Npj Parkinson's Disease, 2018, 4, 22.	5.3	11
269	Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability. Brain Pathology, 2018, 28, 723-734.	4.1	19
270	Noninvasive PK11195â€PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. Journal of Neuroimaging, 2018, 28, 496-505.	2.0	29
271	Integrated magnetic resonance imaging and [¹¹C]â€PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 1186-1197.	5.3	75
272	Dynamic TSPO-PET for assessing early effects of cerebral hypoxia and resuscitation in new born pigs. Nuclear Medicine and Biology, 2018, 66, 49-57.	0.6	6
273	Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2018, 20, 357-364.	2.7	45
274	Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. Neuropsychopharmacology, 2018, 43, 2249-2255.	5.4	33
275	Positron emission tomography imaging in evaluation of MS pathology in vivo. Multiple Sclerosis Journal, 2018, 24, 1399-1412.	3.0	22
276	PET Imaging of T Cells: Target Identification and Feasibility Assessment. ChemMedChem, 2018, 13, 1566-1579.	3.2	1
277	TSPOâ€"PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntingtonâ€™s disease: preclinical evidence with the p75NTR ligand LM11A-31. Human Molecular Genetics, 2018, 27, 2893-2912.	2.9	33

#	Article	IF	Citations
278	Adrenal Steroidogenesis. , 2019, , 56-63.		2
279	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 768-788.	3.4	32
280	Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacologica Sinica, 2019, 40, 351-357.	6.1	39
281	Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 799.	2.8	35
282	Chronic inflammation in multiple sclerosis â€" seeing what was always there. Nature Reviews Neurology, 2019, 15, 582-593.	10.1	81
283	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. Journal of Medicinal Chemistry, 2019, 62, 8235-8248.	6.4	13
284	Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review. Molecular Neuropsychiatry, 2019, 5, 125-146.	2.9	15
285	Frontiers in positron emission tomography imaging of the vulnerable atherosclerotic plaque. Cardiovascular Research, 2019, 115, 1952-1962.	3.8	20
286	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	4.1	173
287	Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. Journal of Neuroscience, 2019, 39, 7218-7226.	3.6	145
288	Effects of age, BMI and sex on the glial cell marker TSPO â€" a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	6.4	70
289	Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography. Journal of Neuroimmunology, 2019, 334, 577000.	2.3	15
290	Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. Future Medicinal Chemistry, 2019, 11, 539-550.	2.3	3
291	Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinsonâ€™s disease. BMC Medical Imaging, 2019, 19, 78.	2.7	7
292	P2X7 PET Radioligand ¹⁸F-PTTP for Differentiation of Lung Tumor from Inflammation. Journal of Nuclear Medicine, 2019, 60, 930-936.	5.0	22
293	Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region. NeuroImage, 2019, 188, 102-110.	4.2	18
294	Binding Affinity of Some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 Polymorphism. International Journal of Molecular Sciences, 2019, 20, 563.	4.1	13
295	Automatic Extraction of a Reference Region for the Noninvasive Quantification of Translocator Protein in Brain Using ¹¹C-PBR28. Journal of Nuclear Medicine, 2019, 60, 978-984.	5.0	14

#	Article	IF	Citations
296	Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 2019, 1, 612-624.	8.5	46
297	Comparative evaluation of ^{99m}Tc-MBIP-X/¹¹[C] MBMP for visualization of 18 kDa translocator protein. New Journal of Chemistry, 2019, 43, 11288-11295.	2.8	8
298	A new perspective for advanced positron emission tomographyâ€“based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
299	A unified structural model of the mammalian translocator protein (TSPO). Journal of Biomolecular NMR, 2019, 73, 347-364.	2.8	12
300	Neuroimaging Biomarkers for Alzheimerâ€™s Disease. Molecular Neurodegeneration, 2019, 14, 21.	10.8	161
301	Modified benzoxazolone (ABOâ€AA) based single photon emission computed tomography (SPECT) probes for 18 kDa translocator protein. Drug Development Research, 2019, 80, 741-749.	2.9	9
302	Opposite microglial activation stages upon loss of <scp>PGRN</scp> or <scp>TREM</scp> 2 result in reduced cerebral glucose metabolism. EMBO Molecular Medicine, 2019, 11, .	6.9	87
303	In vivo direct relation of tau pathology with neuroinflammation in early Alzheimerâ€™s disease. Journal of Neurology, 2019, 266, 2186-2196.	3.6	44
304	Head-to-head comparison of 11C-PBR28 and 11C-ER176 for quantification of the translocator protein in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1822-1829.	6.4	30
305	The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. Brain, Behavior, and Immunity, 2019, 80, 742-750.	4.1	6
306	Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. Organic and Biomolecular Chemistry, 2019, 17, 5086-5098.	2.8	13
307	(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging. European Journal of Medicinal Chemistry, 2019, 176, 410-418.	5.5	14
308	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 6.	3.9	29
309	Neurochemical Aspects of Alzheimerâ€™s Type of Dementia. , 2019, , 73-112.		1
310	Characterization of the High-Affinity Drug Ligand Binding Site of Mouse Recombinant TSPO. International Journal of Molecular Sciences, 2019, 20, 1444.	4.1	10
311	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	2.7	41
312	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Molecular Imaging and Biology, 2019, 21, 935-944.	2.6	32
313	New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Current Neurology and Neuroscience Reports, 2019, 19, 24.	4.2	61

#	Article	IF	Citations
314	Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?. Frontiers in Neurology, 2019, 10, 232.	2.4	48
315	Imaging of neuroinflammation in migraine with aura. Neurology, 2019, 92, e2038-e2050.	1.1	83
316	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.1	69
317	Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. Journal of Neuroscience, 2019, 39, 3752-3769.	3.6	46
318	TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro-Oncology, 2019, 21, 755-764.	1.2	26
319	Detecting neuroinflammation in the brain following chronic alcohol exposure in rats: A comparison between in vivo and in vitro TSPO radioligand binding. European Journal of Neuroscience, 2019, 50, 1831-1842.	2.6	20
320	Seizing the Neuroinflammatory Target: The Quest Continues. Epilepsy Currents, 2019, 19, 379-381.	0.8	5
321	Diagnostic performance of FDG PET in large vessel vasculitis. Clinical and Translational Imaging, 2019, 7, 415-425.	2.1	1
322	Perspectives in TSPO PET Imaging for Neurologic Diseases. Nuclear Medicine and Molecular Imaging, 2019, 53, 382-385.	1.0	5
323	Revisiting the structure of a synthetic somatostatin analogue for peptide drug design. Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2019, 75, 611-620.	1.1	8
324	18F-AzaFol for Detection of Folate Receptor-Î² Positive Macrophages in Experimental Interstitial Lung Diseaseâ€"A Proof-of-Concept Study. Frontiers in Immunology, 2019, 10, 2724.	4.8	27
325	Brain glial activation in fibromyalgia â€" A multi-site positron emission tomography investigation. Brain, Behavior, and Immunity, 2019, 75, 72-83.	4.1	186
326	Photoacoustic microscopy of obesity-induced cerebrovascular alterations. NeuroImage, 2019, 188, 369-379.	4.2	29
327	A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 303-308.	2.2	29
328	The validity of 18F-GE180 as a TSPO imaging agent. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1205-1207.	6.4	36
329	In vivo molecular imaging of neuroinflammation in Alzheimer's disease. Journal of Neurochemistry, 2019, 149, 438-451.	3.9	70
330	Neuroinflammation in schizophrenia: meta-analysis ofin vivomicroglial imaging studies. Psychological Medicine, 2019, 49, 2186-2196.	4.5	151
331	A Proposed Roadmap for Parkinsonâ€™s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	2.8	45

#	Article	IF	Citations
332	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. Schizophrenia Research, 2019, 213, 80-86.	2.0	8
333	Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 580-590.	6.4	52
334	PET imaging of [11C]PBR28 in Parkinsonâ€™s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	6.4	50
335	Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology, 2019, 58, 206-219.	1.9	82
336	Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review. Molecular Psychiatry, 2020, 25, 94-113.	7.9	75
337	Concentration, distribution, and influence of aging on the 18â€‰kDa translocator protein in human brain: Implications for brain imaging studies. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1061-1076.	4.3	13
338	Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by ¹¹C-PBR28 MR-PET. Multiple Sclerosis Journal, 2020, 26, 668-678.	3.0	16
339	Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment. Neurobiology of Aging, 2020, 85, 11-21.	3.1	42
340	Profiles of cortical inflammation in multiple sclerosis by 11C-PBR28 MR-PET and 7 Tesla imaging. Multiple Sclerosis Journal, 2020, 26, 1497-1509.	3.0	22
341	Characterization of the 18 kDa translocator protein (TSPO) expression in postâ€mortem normal and Alzheimer's disease brains. Brain Pathology, 2020, 30, 151-164.	4.1	81
342	Endozepines and their receptors: Structure, functions and pathophysiological significance. , 2020, 208, 107386.		43
343	TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1368-1380.	6.4	42
344	Post mortem evaluation of inflammation, oxidative stress, and PPARÎ³ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration. PLoS ONE, 2020, 15, e0226999.	2.5	8
345	Insight into the Structural Features of TSPO: Implications for Drug Development. Trends in Pharmacological Sciences, 2020, 41, 110-122.	8.7	20
346	Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use. Frontiers in Neuroscience, 2020, 14, 871.	2.8	7
347	Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System. CNS Drugs, 2020, 34, 1229-1251.	5.9	26
348	The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. Cancers, 2020, 12, 2973.	3.7	39
349	PET imaging of neuroinflammation in neurological disorders. Lancet Neurology, The, 2020, 19, 940-950.	10.2	117

#	Article	IF	Citations
350	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry,the, 2020, 7, 1064-1074.	7.4	149
351	Imaging the Neuroimmune Dynamics Across Space and Time. Frontiers in Neuroscience, 2020, 14, 903.	2.8	17
352	Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain, 2020, 143, 3318-3330.	7.6	71
353	No significant elevation of translocator protein binding in the brains of recently abstinent methamphetamine users. Drug and Alcohol Dependence, 2020, 213, 108104.	3.2	7
354	Molecular and Imaging Biomarkers in Alzheimerâ€™s Disease: A Focus on Recent Insights. Journal of Personalized Medicine, 2020, 10, 61.	2.5	35
355	[¹¹C]Methionine and [¹¹C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging, 2020, 19, 153601212096866.	1.4	12
356	Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. ACS Chemical Neuroscience, 2020, 11, 2192-2200.	3.5	13
357	Microglia: Agents of the CNS Pro-Inflammatory Response. Cells, 2020, 9, 1717.	4.1	174
358	The Role of Inflammation after Surgery for Elders (RISE) study: Examination of [11C]PBR28 binding and exploration of its link to post-operative delirium. NeuroImage: Clinical, 2020, 27, 102346.	2.7	17
359	Traditional Chinese medicine for anti-Alzheimerâ€™s disease: berberine and evodiamine from Evodia rutaecarpa. Chinese Medicine, 2020, 15, 82.	4.0	39
360	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	5.5	4
361	Heterogeneity of Neuroinflammatory Responses in Amyotrophic Lateral Sclerosis: A Challenge or an Opportunity?. International Journal of Molecular Sciences, 2020, 21, 7923.	4.1	15
362	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. International Journal of Molecular Sciences, 2020, 21, 6047.	4.1	8
363	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. Frontiers in Neurology, 2020, 11, 541377.	2.4	9
364	Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [11C]Nâ€²-MPB for visualization of 18 kDa TSPO in brain. New Journal of Chemistry, 2020, 44, 7912-7922.	2.8	12
365	PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. Journal of Neuroinflammation, 2020, 17, 140.	7.2	35
366	Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. Biological Psychiatry, 2020, 88, 649-656.	1.3	32
367	Microglial activation and tau burden predict cognitive decline in Alzheimerâ€™s disease. Brain, 2020, 143, 1588-1602.	7.6	113

#	Article	IF	Citations
368	PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nature Communications, 2020, 11, 2360.	12.8	56
369	Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression. International Review of Neurobiology, 2020, 152, 23-40.	2.0	44
370	Gray matter changes related to microglial activation in Alzheimer's disease. Neurobiology of Aging, 2020, 94, 236-242.	3.1	13
371	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	5.0	22
372	Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 2020, 11, 511-517.	3.9	4
373	PET imaging shows no changes in TSPO brain density after IFN-Î± immune challenge in healthy human volunteers. Translational Psychiatry, 2020, 10, 89.	4.8	40
374	Extraâ€Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. Annals of Neurology, 2020, 87, 939-949.	5.3	60
375	In Vivo Imaging of Neuroinflammatory Targets in Treatment-Resistant Epilepsy. Current Neurology and Neuroscience Reports, 2020, 20, 5.	4.2	15
376	Peripheral cytokine and fatty acid associations with neuroinflammation in AD and aMCI patients: An exploratory study. Brain, Behavior, and Immunity, 2020, 87, 679-688.	4.1	19
377	In vivo Characterization of Four 18F-Labeled S1PR1 Tracers for Neuroinflammation. Molecular Imaging and Biology, 2020, 22, 1362-1369.	2.6	13
378	Neuroinflammation and White Matter Alterations in Obesity Assessed by Diffusion Basis Spectrum Imaging. Frontiers in Human Neuroscience, 2019, 13, 464.	2.0	56
379	In-vivo imaging of neuroinflammation in veterans with Gulf War illness. Brain, Behavior, and Immunity, 2020, 87, 498-507.	4.1	80
380	Multimodal Molecular Imaging of the Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1225, 71-87.	1.6	20
381	Correlation of microglial activation with white matter changes in dementia with Lewy bodies. NeuroImage: Clinical, 2020, 25, 102200.	2.7	17
382	Amhr2-Creâ€"Mediated Global Tspo Knockout. Journal of the Endocrine Society, 2020, 4, bvaa001.	0.2	14
383	Infection and Inflammation Imaging. PET Clinics, 2020, 15, 215-229.	3.0	9
384	Anatomy of 18F-GE180, a failed radioligand for the TSPO protein. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2233-2236.	6.4	28
385	Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease. Frontiers in Neurology, 2020, 11, 47.	2.4	18

#	Article	IF	Citations
386	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	1.6	1
387	Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. Journal of Nuclear Medicine, 2020, 61, 1043-1049.	5.0	24
388	Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. Journal of Nuclear Medicine, 2020, 61, 1200-1204.	5.0	8
389	Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2887-2900.	6.4	10
390	Design, Synthesis, and In Silico Evaluation of Methyl 2-(2-(5-Bromo/chloro-2-oxobenzoxazol-3(2H)-yl)-acetamido)-3-phenylpropanoate for TSPO Targeting. Radiochemistry, 2020, 62, 107-118.	0.7	6
391	Biomarkers for Alzheimerâ€™s diseaseâ€"preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 2021, 26, 296-308.	7.9	205
392	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [Fâ€18]FEPPA. Addiction Biology, 2021, 26, e12876.	2.6	10
393	[11C]PBR28 MRâ€"PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Molecular Psychiatry, 2021, 26, 1659-1669.	7.9	35
394	The neuroinflammatory component of negative affect in patients with chronic pain. Molecular Psychiatry, 2021, 26, 864-874.	7.9	42
395	Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depression. Brain, Behavior, and Immunity, 2021, 91, 487-497.	4.1	42
396	Nondisplaceable Binding Is a Potential Confounding Factor in ¹¹C-PBR28 Translocator Protein PET Studies. Journal of Nuclear Medicine, 2021, 62, 412-417.	5.0	10
397	Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharmaceutica Sinica B, 2021, 11, 373-393.	12.0	82
398	Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism and Related Disorders, 2021, 82, 29-36.	2.2	60
399	Early detection and personalized medicine: Future strategies against Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2021, 177, 157-173.	1.7	9
401	Future Imaging in Dementia. Seminars in Nuclear Medicine, 2021, 51, 303-308.	4.6	5
402	An update into the medicinal chemistry of translocator protein (TSPO) ligands. European Journal of Medicinal Chemistry, 2021, 209, 112924.	5.5	31
403	Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with ¹⁸F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism. Journal of Nuclear Medicine, 2021, 62, 536-544.	5.0	31
404	Thalamic neurometabolite alterations in patients with knee osteoarthritis before and after total knee replacement. Pain, 2021, 162, 2014-2023.	4.2	15

#	Article	IF	Citations
405	PET Imaging of Neuroinflammation. , 2021, , 1335-1371.		3
406	Clinical evaluation of neuroinflammation in child-onset focal epilepsy: a translocator protein PET study. Journal of Neuroinflammation, 2021, 18, 8.	7.2	11
407	Association of Early Î²-Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. Neurology, 2021, 96, e1608-e1619.	1.1	30
408	New PET radiopharmaceuticals for imaging CNS diseases. , 2021, , .		0
409	Inflaming the Brain with Iron. Antioxidants, 2021, 10, 61.	5.1	49
410	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
411	Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672.	2.7	21
412	Cellular sources of TSPO expression in healthy and diseased brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 146-163.	6.4	85
413	The Interplay of Cholesterol and Ligand Binding in hTSPO from Classical Molecular Dynamics Simulations. Molecules, 2021, 26, 1250.	3.8	5
414	Detection of Alzheimerâ€™s disease-related neuroinflammation by a PET ligand selective for glial versus vascular translocator protein. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2199245.	4.3	13
415	Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging. ACS Chemical Neuroscience, 2021, 12, 906-916.	3.5	9
416	Imaging Inflammation with Positron Emission Tomography. Biomedicines, 2021, 9, 212.	3.2	24
417	The Ligands of Translocator Protein: Design and Biological Properties. Current Pharmaceutical Design, 2021, 27, 217-237.	1.9	6
418	Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by 18F-FDG- and 11C-PBR28-PET/CT Imaging, and Whole Blood and Muscle Transcriptomics After Immunization of Healthy Humans With Adjuvanted and Unadjuvanted Vaccines. Frontiers in Immunology, 2020, 11, 613496.	4.8	8
419	Is Chelation Therapy a Potential Treatment for Parkinsonâ€™s Disease?. International Journal of Molecular Sciences, 2021, 22, 3338.	4.1	15
420	Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 246-256.	6.4	27
421	Mapping of Translocator Protein (18 kDa) in Peripheral Sterile Inflammatory Disease and Cancer through PET Imaging. Molecular Pharmaceutics, 2021, 18, 1507-1529.	4.6	9
422	Imaging of the glioma microenvironment by TSPO PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 174-185.	6.4	24

#	Article	IF	Citations
423	Supervised clustering for TSPO PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 257-268.	6.4	17
424	Variation rs6971 in the Translocator Protein Gene (TSPO) is Associated with Aggressiveness and Impulsivity but Not with Anxiety in a Population-Representative Sample of Young Adults. Journal of Genetic Psychology, 2021, 182, 149-162.	1.2	1
425	Moving Toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment. Frontiers in Neuroscience, 2021, 15, 639078.	2.8	8
426	Applicability, potential and limitations of TSPO PET imaging as a clinical immunopsychiatry biomarker. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 164-173.	6.4	16
427	Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 1051-1065.	2.6	25
428	Neuroinflammation is highest in areas of disease progression in semantic dementia. Brain, 2021, 144, 1565-1575.	7.6	23
429	Recent advances in pre-clinical diagnosis of Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, , 1.	2.9	3
430	Recent Advances in Neuroimaging of Epilepsy. Neurotherapeutics, 2021, 18, 811-826.	4.4	21
431	Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3925-3939.	6.4	17
432	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Neurotherapeutics, 2021, 18, 686-708.	4.4	19
433	Determination of Hybrid TSPO Ligands with Minimal Impact of SNP (rs6971) through Molecular Docking and MD Simulation Study. Letters in Drug Design and Discovery, 2022, 19, 549-563.	0.7	2
434	The translocator protein gene is associated with endogenous pain modulation and the balance between glutamate and l3-aminobutyric acid in fibromyalgia and healthy subjects: a multimodal neuroimaging study. Pain, 2022, 163, 274-286.	4.2	10
435	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimerâ€™s Brain Tissue. Journal of Alzheimer's Disease, 2021, 80, 1723-1737.	2.6	33
436	A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. Translational Psychiatry, 2021, 11, 334.	4.8	9
437	Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol. BMJ Open, 2021, 11, e044062.	1.9	2
438	Microglia as therapeutic targets after neurological injury: strategy for cell therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 365-380.	3.4	22
439	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
440	Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals. Nuclear Medicine and Biology, 2021, 96-97, 112-147.	0.6	6

#	Article	IF	Citations
441	In vitro and pilot in vivo imaging of 18ÂkDa translocator protein (TSPO) in inflammatory vascular disease. EJNMMI Research, 2021, 11, 45.	2.5	9
442	Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	6.4	2
443	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. Frontiers in Aging Neuroscience, 2021, 13, 624330.	3.4	39
444	Structural determinants of cholesterol recognition in helical integral membrane proteins. Biophysical Journal, 2021, 120, 1592-1604.	0.5	12
445	[¹¹C]PBR28 radiotracer kinetics are not driven by alterations in cerebral blood flow. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3069-3084.	4.3	2
446	What value can TSPO PET bring for epilepsy treatment?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 221-233.	6.4	11
448	Synthesis and Characterization of a â€œClickableâ€•PBR28 TSPO-Selective Ligand Derivative Suitable for the Functionalization of Biodegradable Polymer Nanoparticles. Nanomaterials, 2021, 11, 1693.	4.1	2
449	Exploring Translocator Protein (TSPO) Medicinal Chemistry: An Approach for Targeting Radionuclides and Boron Atoms to Mitochondria. Journal of Medicinal Chemistry, 2021, 64, 9649-9676.	6.4	2
450	Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 137-145.	6.4	5
451	Positron Emission Tomography Techniques to Measure Active Inflammation, Fibrosis and Angiogenesis: Potential for Non-invasive Imaging of Hypertensive Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 719031.	2.4	9
452	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	30.7	235
453	Translation of 11C-labeled tracer synthesis to a CGMP environment as exemplified by [11C]ER176 for PET imaging of human TSPO. Nature Protocols, 2021, 16, 4419-4445.	12.0	7
454	Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain, Behavior, and Immunity, 2021, 96, 154-167.	4.1	16
455	Neuroinflammation in Major Depressive Disorder: A Review of PET Imaging Studies Examining the 18-kDa Translocator Protein. Journal of Affective Disorders, 2021, 292, 642-651.	4.1	26
456	Integrative Neuroinformatics for Precision Prognostication and Personalized Therapeutics in Moderate and Severe Traumatic Brain Injury. Frontiers in Neurology, 2021, 12, 729184.	2.4	13
457	The Translocator Protein (TSPO) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients. Cancers, 2021, 13, 4525.	3.7	4
458	Neuroimmune signatures in chronic low back pain subtypes. Brain, 2022, 145, 1098-1110.	7.6	24
459	Role of Inflammation in Lewy Body Dementia. , 2021, , 190-212.		0

#	Article	IF	Citations
460	Positron emission tomography in multiple sclerosis â€" straight to the target. Nature Reviews Neurology, 2021, 17, 663-675.	10.1	27
461	A pilot [11C]PBR28 PET/MRI study of neuroinflammation and neurodegeneration in chronic stroke patients. Brain, Behavior, & Immunity - Health, 2021, 17, 100336.	2.5	9
462	PET Imaging of Peripheral Benzodiazepine Receptor Standard Uptake Value Increases After Controlled Cortical Impact, a Rodent Model of Traumatic Brain Injury. ASN Neuro, 2021, 13, 175909142110141.	2.7	1
463	Synthesis and pharmacological evaluation of [¹⁸F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971. RSC Medicinal Chemistry, 2021, 12, 1207-1221.	3.9	7
464	Positron Emission Tomography in Drug Development. , 2021, , 165-181.		1
465	Imaging of Microglial Activation in Alzheimerâ€™s Disease by [11C]PBR28 PET. Methods in Molecular Biology, 2018, 1750, 323-339.	0.9	7
466	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
467	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2021, , 1021-1040.		2
468	PARP1 Gene Variation and Microglial Activity on [11C]PBR28 PET in Older Adults at Risk for Alzheimerâ€™s Disease. Lecture Notes in Computer Science, 2013, 8159, 150-158.	1.3	8
469	Radioligands for Imaging Vesicular Monoamine Transporters. , 2014, , 765-790.		4
470	Membrane-embedded TSPO: an NMR view. European Biophysics Journal, 2021, 50, 173-180.	2.2	3
471	TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis. Seminars in Neurology, 2017, 37, 546-557.	1.4	9
472	Neuroimaging in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 18-27.	1.7	21
473	Thalamic neuroinflammation as a reproducible and discriminating signature for chronic low back pain. Pain, 2021, 162, 1241-1249.	4.2	24
475	Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI. EJNMMI Research, 2019, 9, 113.	2.5	10
476	[18F]FEPPA PET imaging for monitoring CD68-positive microglia/macrophage neuroinflammation in nonhuman primates. EJNMMI Research, 2020, 10, 93.	2.5	15
477	Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease. EJNMMI Research, 2020, 10, 147.	2.5	5
478	Image Derived Input Function for [18F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. PLoS ONE, 2014, 9, e115768.	2.5	11

#	Article	IF	Citations
479	Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. PLoS ONE, 2017, 12, e0177785.	2.5	20
480	The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory â€˜M1â€™ human macrophages. PLoS ONE, 2017, 12, e0185767.	2.5	59
481	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	2.7	48
482	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. Journal of Psychiatry and Neuroscience, 2019, 44, 111-119.	2.4	26
483	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. Current Medicinal Chemistry, 2016, 23, 1818-1869.	2.4	149
484	PET Radioligands for In Vivo Visualization of Neuroinflammation. Current Pharmaceutical Design, 2014, 20, 5897-5913.	1.9	42
485	Investigational PET tracers for high-grade gliomas. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 281-294.	0.7	10
486	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. Efficacy and Mechanism Evaluation, 2020, 7, 1-26.	0.7	5
487	Completing the Pain Circuit: Recent Advances in Imaging Pain and Inflammation beyond the Central Nervous System. Rambam Maimonides Medical Journal, 2013, 4, e0026.	1.0	3
488	Translocator protein (TSPO): the new story of the old protein in neuroinflammation. BMB Reports, 2020, 53, 20-27.	2.4	70
489	We need to talk about reliability: making better use of test-retest studies for study design and interpretation. PeerJ, 2019, 7, e6918.	2.0	121
490	Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa*. Australian Journal of Chemistry, 2021, , .	0.9	1
491	The aryl hydrocarbon receptor: A diagnostic and therapeutic target in glioma. Drug Discovery Today, 2022, 27, 422-435.	6.4	5
492	Imaging brain cortisol regulation in PTSD with a target for 11Î²-hydroxysteroid dehydrogenase type 1. Journal of Clinical Investigation, 2021, 131, .	8.2	10
493	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. Neuromethods, 2022, , 407-427.	0.3	2
494	Imaging the influence of red blood cell docosahexaenoic acid status on the expression of the 18KDa translocator protein in the brain: a [11C]PBR28 PET study in young healthy males. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.5	2
495	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
496	Association of the tissue microstructural diffusivity and translocator protein PET in Gulf War Illness. Brain, Behavior, & Immunity - Health, 2021, 18, 100364.	2.5	2

#	Article	IF	Citations
497	In Vivo Imaging of Neuroinflammation in Acute Brain Injury. , 2014, , 235-248.		0
498	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
499	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2014, , 653-667.		0
500	PET Imaging in Multiple Sclerosis: Focus on the Translocator Protein. , 2014, , 757-773.		1
501	PET Imaging in Neuroinflammation. , 2014, , 205-216.		0
506	Multimodality Preclinical Imaging in Inflammatory Diseases. , 2019, , 135-160.		0
509	Basic Science of PET Imaging for Inflammatory Diseases. , 2020, , 1-42.		2
511	PET Imaging of Vesicular Monoamine Transporters. , 2021, , 1091-1132.		0
513	Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. Journal of Neurology, 2022, 269, 2304-2314.	3.6	18
514	Molecular Imaging. , 2020, , 145-159.		1
515	Molecular Imaging in Infection and Inflammation. , 2021, , 281-291.		0
516	Molecular Imaging of Depressive Disorders. , 2021, , 85-207.		3
517	TSPO Imaging in Psychiatric Disorders. , 2021, , 589-606.		0
518	Personality traits in psychosis and psychosis risk linked to TSPO expression: a neuroimmune marker. Personality Neuroscience, 2020, 3, e14.	1.6	1
519	Coexistence of cerebral hypometabolism and neuroinflammation in the thalamo-limbic-brainstem region in young women with functional somatic syndrome. EJNMMI Research, 2020, 10, 29.	2.5	1
520	Imaging translocator protein expression with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 74.	6.4	4
522	PET and SPECT Imaging in Atypical Parkinsonian Syndromes. , 2021, , 729-757.		0
523	PET Imaging in Multiple Sclerosis. , 2021, , 893-916.		2

#	Article	IF	Citations
524	Neuroinflammation: From Target Selection to Preclinical and Clinical Studies. , 2021, , 567-592.		1
525	Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET. Clinical Nuclear Medicine, 2021, 46, 136-137.	1.3	6
529	Inflammation in migraineâ€¦or notâ€¦: A critical evaluation of the evidence. Headache, 2021, 61, 1575-1578.	3.9	4
531	Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization. , 2022, 234, 108048.		42
532	Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising ¹⁸F-Labeled Ligand. Journal of Medicinal Chemistry, 2021, 64, 16731-16745.	6.4	15
533	Microglial Activation and Neuroinflammation. , 2022, , 191-196.		0
534	Dopamine and Neuroinflammation in Schizophrenia â€“ Interpreting the Findings from Translocator Protein (18kDa) PET Imaging. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3345-3357.	2.2	2
535	InÂVivo Evaluation of 6 Analogs of ¹¹C-ER176 as Candidate ¹⁸F-Labeled Radioligands for 18-kDa Translocator Protein. Journal of Nuclear Medicine, 2022, 63, 1252-1258.	5.0	10
536	Positron Emission Tomography in Animal Models of Tauopathies. Frontiers in Aging Neuroscience, 2021, 13, 761913.	3.4	9
537	Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update. European Journal of Neuroscience, 2022, 55, 1322-1343.	2.6	27
538	Neuroimaging with PET/CT in chronic traumatic encephalopathy: what nuclear medicine can do to move the field forward. Expert Review of Molecular Diagnostics, 2022, 22, 149-156.	3.1	8
539	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. Cancers, 2022, 14, 53.	3.7	12
540	Gamma camera imaging in psychiatric disorders. , 2022, , .		0
541	Principal Component Analysis versus Subjectâ€™s Residual Profile Analysis for Neuroinflammation Investigation in Parkinson Patients: A PET Brain Imaging Study. Journal of Imaging, 2022, 8, 56.	3.0	3
542	Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 2022, 22, 657-673.	22.7	360
543	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Current Medicinal Chemistry, 2022, 29, 4862-4890.	2.4	9
544	Differential effects of the translocator protein 18ÂkDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment. Psychopharmacology, 2022, , 1.	3.1	0
545	Efficient and automatic synthesis of TSPO PET ligand [18F]-GE-180 and its application in rheumatoid arthritis model. Applied Radiation and Isotopes, 2022, 184, 110213.	1.5	1

#	Article	IF	Citations
546	Molecular neuroimaging of inflammation in HIV. Clinical and Experimental Immunology, 2022, 210, 14-23.	2.6	2
547	The 18-kDa Translocator Protein PET Tracers as a Diagnostic Marker for Neuroinflammation: Development and Current Standing. ACS Omega, 2022, 7, 14412-14429.	3.5	16
548	Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases. Current Medicinal Chemistry, 2022, 29, .	2.4	4
549	Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder: A Review. Frontiers in Neuroscience, 2022, 16, 806876.	2.8	7
553	Translocator Protein (18 kDa) Polymorphism (rs6971) in the Korean Population. Dementia and Neurocognitive Disorders, 2022, 21, 71.	1.4	3
554	Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. International Journal of Molecular Sciences, 2022, 23, 5023.	4.1	64
555	Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimerâ€™s Disease. Molecules, 2022, 27, 2780.	3.8	10
556	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. Journal of Neurochemistry, 2023, 164, 364-400.	3.9	7
557	Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by TSPO. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
558	Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method. Diagnostics, 2022, 12, 1161.	2.6	7
559	Radiosynthesis and initial preclinical evaluation of [11C]AZD1283 as a potential P2Y12R PET radiotracer. Nuclear Medicine and Biology, 2022, 114-115, 143-150.	0.6	3
560	Imaging Neuroinflammation in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 45S-52S.	5.0	22
561	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Frontiers in Medicine, 0, 9, .	2.6	13
562	The functional and structural associations of aberrant microglial activity in major depressive disorder. Journal of Psychiatry and Neuroscience, 2022, 47, E197-E208.	2.4	8
563	Tracers progress for positron emission tomography imaging of glial-related disease. Journal of Biomedical Research, 2022, 36, 1.	1.6	1
564	[¹⁸F]BIBD-239: ¹⁸F-Labeled ER176, a Positron Emission Tomography Tracer Specific for the Translocator Protein. Molecular Pharmaceutics, 2022, 19, 2351-2366.	4.6	5
566	Alzheimerâ€™s disease: a scoping review of biomarker research and development for effective disease diagnosis. Expert Review of Molecular Diagnostics, 2022, 22, 681-703.	3.1	5
567	Brain microglia activation and peripheral adaptive immunity in Parkinsonâ€™s disease: a multimodal PET study. Journal of Neuroinflammation, 2022, 19, .	7.2	21

#	Article	IF	Citations
568	Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder. , 0, , .		0
569	Molecular Imaging in Parkinsonian Disordersâ€"Whatâ€™s New and Hot?. Brain Sciences, 2022, 12, 1146.	2.3	8
570	Acetamidobenzoxazolone scaffold as a promising translocator protein (18â€‰kDa, TSPO) marker for neuroinflammation imaging: Advancement in last decennial period. Drug Development Research, 2022, 83, 1519-1533.	2.9	3
571	Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain. BMJ Open, 2022, 12, e063613.	1.9	2
573	Meta-analysis of molecular imaging of translocator protein in major depression. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	5
575	[18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinsonâ€™s Disease. Cells, 2022, 11, 3081.	4.1	2
577	Assessing organ-level immunoreactivity in a rat model of sepsis using TSPO PET imaging. Frontiers in Immunology, 0, 13, .	4.8	0
579	PET Imaging of Fructose Metabolism in a Rodent Model of Neuroinflammation with 6-[18F]fluoro-6-deoxy-D-fructose. Molecules, 2022, 27, 8529.	3.8	3
580	Assessing the potential anti-neuroinflammatory effect of minocycline in chronic low back pain: Protocol for a randomized, double-blind, placebo-controlled trial. Contemporary Clinical Trials, 2023, 126, 107087.	1.8	2
581	Molecular Imaging of Neuroinflammation in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Advances in Experimental Medicine and Biology, 2023, , 301-326.	1.6	0
582	In vivo characterization of microglia and myelin relation in multiple sclerosis by combined 11C-PBR28 PET and synthetic MRI. Journal of Neurology, 0, , .	3.6	0
583	A feasibility study for quantitative assessment of cerebrovascular malformations using flutriciclamide ([18F]GE-180) PET/MRI. Frontiers in Medicine, 0, 10, .	2.6	2
584	Positron Emission Tomography Imaging in Vasculitis. Cardiology Clinics, 2023, 41, 251-265.	2.2	4
585	Multimodal comparisons of QSM and PET in neurodegeneration and aging. NeuroImage, 2023, 273, 120068.	4.2	9
586	Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer. Journal of Nuclear Medicine, 2023, 64, 508-514.	5.0	1
587	Quantitative assessment of translocator protein (TSPO) in the non-human primate brain and clinical translation of [18F]LW223 as a TSPO-targeted PET radioligand. Pharmacological Research, 2023, 189, 106681.	7.1	2
588	Inflammatory Immune Process and Depression-like Behavior in Hypothyroid Rats: A [18F] DPA-714 Micro Positron Emission Tomography Study. Pharmaceuticals, 2023, 16, 279.	3.8	1
589	Radiation-induced neuroinflammation monitoring by the level of peripheral blood monocytes with high expression of translocator protein. International Journal of Radiation Biology, 2023, 99, 1364-1377.	1.8	0

#	Article	IF	Citations
590	Brain and Systemic Inflammation in De Novo Parkinson's Disease. Movement Disorders, 2023, 38, 743-754.	3.9	12
591	Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers. Current Cardiovascular Imaging Reports, 2023, 16, 1-9.	0.6	1
592	Imaging of Brain Structural and Functional Effects in People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2023, 227, S16-S29.	4.0	2
593	Characterization of neuroinflammation pattern in anti-LGI1 encephalitis based on TSPO PET and symptom clustering analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2394-2408.	6.4	2
594	New TSPO Crystal Structures of Mutant and Heme-Bound Forms with Altered Flexibility, Ligand Binding, and Porphyrin Degradation Activity. Biochemistry, 2023, 62, 1262-1273.	2.5	4
595	A PET-CT study on neuroinflammation in Huntingtonâ€™s disease patients participating in a randomized trial with laquinimod. Brain Communications, 2023, 5, .	3.3	3
596	Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. Journal of Neuroinflammation, 2023, 20, .	7.2	2
597	Positron Emission Tomography with [<scp>¹⁸F</scp>]â€<scp>DPA</scp>â€714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Annals of Neurology, 2023, 94, 366-383.	5.3	8
600	[18F]DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 3251-3264.	6.4	3
601	Clinical Radiosynthesis and Translation of [¹⁸F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages. ACS Chemical Neuroscience, 2023, 14, 2416-2424.	3.5	1
602	Choroid Plexus Calcification Correlates with Cortical Microglial Activation in Humans: A Multimodal PET, CT, MRI Study. American Journal of Neuroradiology, 2023, 44, 776-782.	2.4	1
603	Contribution of neuroimaging studies to the understanding of immunology and inflammation in epilepsy. , 2023, , 411-423.		0
604	The comorbidity of depression and neurocognitive disorder in persons with HIV infection: call for investigation and treatment. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	3
605	Translocator protein PET imaging in temporal lobe epilepsy: A reliable test-retest study using asymmetry index. , 0, 2, .		0
606	Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 1588-1600.	4.3	3
607	Imaging immunomodulatory treatment responses in a multiple sclerosis mouse model using hyperpolarized 13C metabolic MRI. Communications Medicine, 2023, 3, .	4.2	2
608	Measuring Pathology in Patients with Multiple Sclerosis Using Positron Emission Tomography. Current Neurology and Neuroscience Reports, 2023, 23, 479-488.	4.2	2
609	Individual regional associations between AÎ²-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies. Molecular Psychiatry, 2023, 28, 4438-4450.	7.9	7

#	Article	IF	Citations
610	TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain, Behavior, and Immunity, 2023, 113, 415-431.	4.1	3
611	Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism. EJNMMI Research, 2023, 13, .	2.5	2
612	Thalamic neurometabolite alterations in chronic low back pain: a common phenomenon across musculoskeletal pain conditions?. Pain, 2023, , .	4.2	0
613	Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nature Communications, 2023, 14, .	12.8	12
614	Concussion: Beyond the Cascade. Cells, 2023, 12, 2128.	4.1	3
615	Development and Initial Assessment of [18F]OP-801: a Novel Hydroxyl Dendrimer PET Tracer for Preclinical Imaging of Innate Immune Activation in the Whole Body and Brain. Molecular Imaging and Biology, 2023, 25, 1063-1072.	2.6	0
616	Positron Emission Tomography (PET) Imaging Biomarkers in Huntingtonâ€™s Disease. Contemporary Clinical Neuroscience, 2023, , 127-158.	0.3	0
617	The mitochondrial protein TSPO in Alzheimerâ€™s disease: relation to the severity of AD pathology and the neuroinflammatory environment. Journal of Neuroinflammation, 2023, 20, .	7.2	2
618	PET imaging of microglia using PBR28suv determines therapeutic efficacy of autologous bone marrow mononuclear cells therapy in traumatic brain injury. Scientific Reports, 2023, 13, .	3.3	0
620	Imaging the brainâ€™s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography. Molecular Psychiatry, 2023, 28, 3384-3390.	7.9	0
621	Deriving Physiological Information fromÂPET Images Using Machine Learning. Lecture Notes in Computer Science, 2023, , 26-37.	1.3	0
622	[18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy. Neurology, 2023, , .	1.1	0
623	[¹⁸F]LW223 has low non-displaceable binding in murine brain, enabling high sensitivity TSPO PET imaging. Journal of Cerebral Blood Flow and Metabolism, 2024, 44, 397-406.	4.3	1
624	Integrating TSPO PET imaging and transcriptomics to unveil the role of neuroinflammation and amyloid-Î² deposition in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 455-467.	6.4	1
627	Quantitative Analysis of S1PR1 Expression in the Postmortem Multiple Sclerosis Central Nervous System. ACS Chemical Neuroscience, 2023, 14, 4039-4050.	3.5	0
628	Glial dysfunction in substance use disorders. New insights from PET and MR imaging. Addiction Neuroscience, 2023, 9, 100135.	1.3	0
629	Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease. JAMA Network Open, 2023, 6, e2345175.	5.9	3
630	The mitochondrial translocator protein (TSPO, 18ÂkDa): A key multifunctional molecule in liver diseases. Biochimie, 2023, , .	2.6	0

#	Article	IF	Citations
631	[11C]-PBR28 positron emission tomography signal as an imaging marker of joint inflammation in knee osteoarthritis. Pain, 0, , .	4.2	0
632	PET Biomarkers in Psychiatry. , 2023, , 81-104.		0
633	Radiotracers for Imaging of Inflammatory Biomarkers TSPO and COX-2 in the Brain and in the Periphery. International Journal of Molecular Sciences, 2023, 24, 17419.	4.1	1
634	The development status of PET radiotracers for evaluating neuroinflammation. Nuclear Medicine and Molecular Imaging, 0, , .	1.0	0
635	Among the recombinant TSPOs, the BcTSPO. Biochimie, 2024, , .	2.6	0
636	Sexually dimorphic murine brain uptake of the 18â€…kDa translocator protein PET radiotracer [18F]LW223. Brain Communications, 2023, 6, .	3.3	0
637	Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model. Alzheimer's and Dementia, 2024, 20, 2397-2407.	0.8	1
638	Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
639	PET Imaging to Measure Neuroinflammation In Vivo. Methods in Molecular Biology, 2024, , 177-193.	0.9	0
640	Biomarkers for Alzheimer's Disease â€“ An Overview. Macromolecular Symposia, 2024, 413, .	0.7	0
641	Microglial Activation Imaging Using ¹⁸F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis. Radiology, 2024, 310, .	7.3	0